Maverick Therapeutics

Takeda buys Maverick as T-Cell engager research hots up

Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace. San Francisco-based Maverick’s technology is designed to target solid tumours with a T-cell attack that focuses on cancerous tissues while leaving healthy tissue alone. Standard T-cell …

Takeda buys Maverick as T-Cell engager research hots up Read More »

Takeda to buy out Maverick in $525M bet on bringing T cells to solid tumors

Takeda Pharmaceutical and Maverick Therapeutics have been R&D partners since 2017. In buying out its partner, Takeda acquires technology and drug candidates that could offer advantages compared to CAR-T therapies, including the potential to treat solid tumors.